Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 4,126 shares at $57.10 ($236K) on 2026-10-05, disclosed to the SEC on 2026-10-05.
Scheduled sale ($236k) by EVP, Research & Investments under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RPRX | SELL | 2026-06-25 | $502K | — | Filing → |
| RPRX | SELL | 2026-05-21 | $722K | — | Filing → |
| RPRX | SELL | 2026-05-15 | $726K | — | Filing → |